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The chemokine receptor CXCR4 is rapidly targeted for lyso-
somal degradation by the E3 ubiquitin ligase atrophin-interact-
ing protein 4 (AIP4). Although it is known that AIP4 mediates
ubiquitination and degradation of CXCR4 and that perturba-
tions in these events contribute to disease, the mechanisms
mediating AIP4-dependent regulation of CXCR4 degrada-
tion remain poorly understood. Here we show that AIP4
directly interacts with the amino-terminal half of nonvisual
arrestin-2 via its WW domains. We show that depletion of
arrestin-2 by small interfering RNA blocks agonist-promoted
degradation of CXCR4 by preventing CXCR4 trafficking from
early endosomes to lysosomes. Surprisingly, CXCR4 internal-
ization and ubiquitination remain intact, suggesting that the
interaction between arrestin-2 and AIP4 is not required for
ubiquitination of the receptor at the plasma membrane but
perhaps for a later post-internalization event. Accordingly,
we show that activation of CXCR4 promotes the interaction
between AIP4 and arrestin-2 that is consistent with a time
when AIP4 co-localizes with arrestin-2 on endocytic vesicles.
Taken together, our data suggest that the AIP4arrestin-2
complex functions on endosomes to regulate sorting of
CXCR4 into the degradative pathway.
The chemokine receptor CXCR4, a G protein-coupled
receptor (GPCR),3 together with its cognate ligand, stromal
cell-derived factor-1, also termed CXCL12, play an important
role in several biological processes such as development of the
heart and brain, leukocyte chemotaxis, and stem cell homing
(1–3). Although CXCR4 dysregulation has been linked to sev-
eral pathologies, especially cancer, the molecular mechanisms
regulating CXCR4 remain poorly understood (4, 5). Acti-
vated CXCR4 is targeted for lysosomal degradation through
a pathway involving ubiquitination of carboxyl-terminal tail
lysine residues mediated by the E3 ubiquitin ligase atrophin-
interacting protein 4 (AIP4) (6, 7). AIP4 belongs to the neural
precursor cell-expressed developmentally down-regulated
gene 4-like family of homologous to E6-AP carboxyl-terminal
domain E3 ubiquitin ligases, which interact with their target
proteins either directly or indirectly via their WW domains or
possibly other domains (8, 9).
In addition, AIP4 regulates endosomal sorting of activated
CXCR4 by targeting the receptor to the endosomal sorting
complex required for transport pathway (7), which is a complex
network of proteins that recognize and sort ubiquitinated cargo
into the multivesicular body (10). Entry into this pathway
requires the action of HRS, a ubiquitin-binding protein local-
ized to flat clathrin lattices on endosomes adjacent to invagi-
nating domains, where it sequesters ubiquitinated cargo des-
tined for entry into the multivesicular body for subsequent
degradation (11, 12). CXCR4 andAIP4 localize toHRS-positive
microdomains on endosomes (7). In addition, AIP4 mediates
CXCR4-dependent ubiquitination of HRS, an action that likely
plays a role in the sorting function of HRS (7). Whether addi-
tional proteins play a role in the endosomal sorting of CXCR4,
however, remains to be determined.
Nonvisual arrestins, arrestin-2 and arrestin-3 (also termed
-arrestin-1 and -arrestin-2, respectively), function in GPCR
desensitization and also serve as endocytic adaptors to recruit
phosphorylated receptors for internalization through clathrin-
coated pits (13). Arrestins have also been implicated in ubiq-
uitination of GPCRs. Ubiquitination of the 2-adrenergic
receptor appears to require arrestin-3 and a yet to be identified
E3 ubiquitin ligase (14). Arrestins have also been implicated in
CXCR4 desensitization (15, 16) and are thought to play a role
in CXCR4 internalization (15, 17), but whether they function in
ubiquitination and degradation of activated CXCR4 remains
unknown. Therefore, to gain further insight into the molecular
mechanismsmediating CXCR4 down-regulation, we examined
the role of nonvisual arrestins in targeting CXCR4 to the deg-
radative pathway.
* This work was supported in part by a Scientist Development Grant from
the American Heart Association (to A. M.) and National Institutes of
Health Grants GM075159 (to A. M.) and GM47417 (to J. L. B.). The costs of
publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement”
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Supported by a predoctoral fellowship from the American Heart
Association.
2 To whom correspondence should be addressed: Dept. of Pharmacology,
Loyola University Chicago, Stritch School of Medicine, 2160 S. 1st Ave.,
Bldg.101/Rm. 2721, Maywood, IL 60153. Tel.: 708-216-3456; Fax: 708-216-
6596; E-mail: amarchese@lumc.edu.
3 The abbreviations used are: GPCR, G protein-coupled receptor; AIP4, atrophin-
interacting protein 4; GST, glutathione S-transferase; E3, ubiquitin-protein
isopeptide ligase; siRNA, small interfering RNA; DMEM, Dulbecco’s modified
Eagle’s medium; FBS, fetal bovine serum; HA, hemagglutinin; WCL, whole cell
lysates; HRS, hepatocyte growth factor-regulated tyrosine kinase substrate; IP,
immuno precipitation.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 282, NO. 51, pp. 36971–36979, December 21, 2007
© 2007 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
DECEMBER 21, 2007 • VOLUME 282 • NUMBER 51 JOURNAL OF BIOLOGICAL CHEMISTRY 36971
This is an Open Access article under the CC BY license.
EXPERIMENTAL PROCEDURES
Cell Lines, cDNA Constructs, Antibodies, and siRNA—
HEK293 (Microbix, Toronto, Canada) and HeLa cells (Ameri-
can Type Culture Collection) were maintained in Dulbecco’s
modified Eagle’s medium (DMEM; Mediatech, Inc., Herndon,
VA) supplemented with fetal bovine serum (FBS; Atlanta Bio-
logicals, Lawrenceville, GA). HA-tagged CXCR4 in pcDNA3
and FLAG-tagged ubiquitin andAIP4 in pCMV-10were as pre-
viously described (7). For GST fusion constructs, full-length
AIP4 (amino acids 2–862) andWWdomains I–IV (amino acids
260–486) were amplified by PCR and cloned into pGEX-4T2.
HA-CXCR4 was amplified by PCR and subcloned into the
EcoRI and ApaI sites of pEYFP-N1 (Clontech, Mountain View,
CA). Full-length AIP4 was amplified by PCR and subcloned
into the KpnI and BamHI sites of a plasmid encoding mono-
meric Cherry (pmCh), kindly provided by Dr. R. Y. Tsien
(Howard Hughes Medical Institute, University of California,
SanDiego) (18). Arrestin-2was subcloned into theXhoI andApaI
sites of pEYFP-C1. All of the constructs were sequenced to verify
that no errorswere introduced by the PCR.GST fusion constructs
of the four individual AIP4 WW domains were as described (19)
and kindly provided by Dr. Tony Pawson (Mount Sinai Hospital,
Toronto, Canada). The anti-CXCR4 ratmonoclonal antibodywas
as previously described (6). The anti-HA monoclonal and poly-
clonal antibodies were from Covance (Berkeley, CA). The anti-
FLAGM2 and M2-HRP monoclonal antibodies and FLAG poly-
clonal antibody were from Sigma-Aldrich. The anti--tubulin
monoclonal antibody was fromAccurate Chemical and Scientific
(Westbury, NY). The anti-actin monoclonal antibody was from
MP Biomedicals (Aurora, OH). The anti-EEA1 mouse mono-
clonal antibodywas fromBDBiosciences (San Jose,CA).The anti-
LAMP2 (H4B4) antibody was from the Developmental Studies
Hybridoma Bank at the University of Iowa. Alexa 594-conjugated
anti-mouse antibody was from Invitrogen. The anti-AIP4 mouse
monoclonal (G11) and goat polyclonal (D20) antibodies and iso-
type controls were from Santa Cruz Biotechnology (Santa Cruz,
CA). Mouse, goat, and rabbit anti-IgG antibody horseradish con-
jugateswere fromVectorLaboratories (Burlingame,CA).Ratanti-
IgG antibody horseradish conjugate was from Jackson Immu-
noResearch (West Grove, PA). The control siRNA and the siRNA
for arrestin-2 and arrestin-3 were from the siGENOME SMART-
pool commercially purchased from Dharmacon RNA Technolo-
gies (Lafayette, CO). The sequence of the siRNA that targets both
human arrestin-2 (nucleotides 179–190 with respect to the start
codon) and arrestin-3 (nucleotides 175–193 with respect to the A
of the start codon) is 5-ACCUGCGCCUUCCGCUAUG-3 and
was also from Dharmacon. Stromal cell-derived factor-1 (also
called CXCL12) was from PeproTech (Rocky Hill, NJ).
Degradation Assay—Agonist-promoted degradation of HA-
tagged CXCR4 in HEK293 cells and endogenous CXCR4 in
HeLa cells was detected by immunoblot analysis, as previously
described (7). Briefly, the cells were treated with vehicle
(DMEM  0.5% FBS) or CXCL12 (10 nM) in the presence of 50
g/ml cycloheximide (to prevent protein synthesis) for 3 h.We
have found that 10 nM CXCL12 produces the same level of
CXCR4 degradation as 100 nM CXCL12 (20). The cells were
directly lysed in 2 sample buffer, and receptor levels were
detected as we have previously shown (6, 7, 20, 21). For RNA
interference experiments, HeLa cells were transfected with
control siRNA or siRNA directed against arrestin-2 (100 nM),
arrestin-3 (100 nM), or arrestin-2 and arrestin-3 together (50 nM
each) using Lipofectamine 2000, according to the manufactur-
er’s instructions. For studies in HEK293 cells, the cells were
transfected with siRNA as described for HeLa cells, followed by
transfection with HA-CXCR4 the following day using FuGENE
6 transfection reagent, according to the manufacturer’s
instructions.
Detection of Ubiquitinated CXCR4—HEK293 cells grown on
10-cm dishes were transfected with arrestin-2, arrestin-3,
arrestin-2/3, and control siRNAas described above, followed by
co-transfection of HA-CXCR4 and FLAG-ubiquitin the next
day. Detection of ubiquitinated CXCR4 was as previously
described (7).
Measuring Receptor Internalization—HEK293 cells grown
on10-cmdisheswere transfectedwith siRNA for arrestin-2 and
control siRNA as described above, followed by co-transfection
of HA-CXCR4 the next day. Receptor internalization was
measured by cell surface enzyme-linked immunosorbent assay,
as previously described (6).
Co-immunoprecipitation Studies—HEK293 cells stably
expressing HA-tagged CXCR4 were serum-starved in DMEM
supplemented with 0.5% FBS overnight (14–16 h) followed by
treatment with the same medium without or with 30 nM
CXCL12 for 15, 30, and 60min.After stimulation, the cells were
placed on ice, lysed in ice-cold immunoprecipitation buffer (20
mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Triton X-100, phos-
phatase inhibitor cocktails I and II (Sigma), and protease inhib-
itors (10 g/ml aprotinin, 10 g/ml leupeptin, and 10 g/ml
pepstatin A)). The lysates were clarified by centrifugation at
21,000  g for 20 min at 4 °C, and equal amounts of clarified
lysates were processed. An anti-AIP4 monoclonal antibody
(G11; Santa Cruz) was used to immunoprecipitate endog-
enously expressed AIP4 in HEK293 cells, essentially as previ-
ously described (7), followed by SDS-PAGE and immunoblot-
ting to detect endogenous arrestins.
GST Pulldowns—Escherichia coli BL21 cells transformed
withGST fusion constructs were grown overnight at 37 °C. The
following day, the cultures were diluted 1:50 and grown to an
A600  0.4–0.5 at 37 °C and then induced with 500 M isopro-
pyl-1-thio--D-galactopyranoside for 3 h at 18 °C. The cells
were pelleted, resuspended in binding buffer (20 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 0.1% Triton X-100, 1 mM dithiothreitol,
10 g/ml leupeptin, 10 g/ml pepstatin A, and 10 g/ml apro-
tinin), and sonicated on ice. The lysates were clarified by cen-
trifugation for 20 min at 21,000  g at 4 °C followed by incuba-
tion with glutathione-Sepharose 4B beads overnight at 4 °C
while rocking. The samples were washed and resuspended in
binding buffer. For binding experiments using transfected cells,
1–3 g of GST fusion proteins were incubated with cell lysates
prepared from HEK293 cells expressing the protein of interest
for 12–16 h. The samples were washed three times in binding
buffer, eluted in 2 sample buffer by boiling for 10 min, and
analyzed by SDS-PAGE and Western blotting. For binding
experiments using purified proteins, 1g ofGST fusion protein
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was incubated with 300 ng of purified arrestin-2 for 1 h and
processed in the same manner.
Immunofluorescence Microscopy—HEK293 cells were trans-
fected with arrestin-2 siRNA followed by transfection of HA-
CXCR4 tagged with yellow fluorescent protein at its carboxyl-
terminal end (HA-CXCR4-YFP). The cells were treated with
CXCL12 for 3 h, followed by fixation, permeabilization, and
immunostaining for EEA1 and LAMP2. For AIP4 and arres-
tin-2 co-localization experiments, HEK293 cells transiently co-
transfected with HA-CXCR4, mCh-AIP4, and YFP-arrestin-2
were serum-starved for 14–16 h in DMEM containing 0.5%
FBS and treated with vehicle or 30 nM CXCL12 for 30 min
followed by permeabilization and fixation. The images were
acquired using a Zeiss LSM 510 laser scanning confocal imag-
ing system with a 63 W Apochromat objective at 512  512
resolution. The acquired images were analyzed using Image J
1.3v software (NIH).
Statistical Analysis—The data were analyzed and subjected




and ubiquitination, we initially examined the effect of siRNA-
mediated depletion of arrestin-2 and arrestin-3 on agonist pro-
moted degradation of endogenous CXCR4 in HeLa cells. As
shown in Fig. 1 (A and B), agonist-promoted degradation of
CXCR4 was inhibited in cells transfected with either arrestin-2
or arrestin-3 siRNA or both, suggesting that arrestins are
involved in agonist-promoted degradation of CXCR4. Interest-
ingly, inhibition of CXCR4 degradation was more pronounced
in cells depleted of arrestin-2 compared with arrestin-3, even
though the siRNA-mediated depletion of arrestin-3was consis-
tently greater than depletion of arrestin-2, suggesting a more
important role for arrestin-2 in degradation of activated
CXCR4.
Wenext examined the role of arrestin-2 in agonist-promoted
CXCR4 degradation in HEK293 cells, a model cell line used
previously to study CXCR4 trafficking (6, 7). We found that
degradation of HA-tagged CXCR4 induced by agonist was sig-
nificantly inhibited in arrestin-2-depleted cells as compared
with control siRNA transfected cells (Fig. 1, C and D), consist-
ent with that observed with endogenous CXCR4 in HeLa cells.
We have previously shown that internalization is a prerequisite
for degradation (6), and because arrestins are thought to play a
role in CXCR4 internalization (15, 17), we next determined
whether inhibition of internalization could account for the
attenuated degradation observed in the arrestin-2 siRNA-
treated cells. HEK293 cells were transfected with siRNA target-
ing arrestin-2 or control siRNA together with HA-tagged
CXCR4, and receptor internalization was assessed by cell sur-
face enzyme-linked immunosorbent assay, as previously
described (6). As shown in Fig. 1E, agonist-promoted internaliza-
tion of CXCR4 in arrestin-2-depleted cells was similar to that in
control siRNA-transfected cells, suggesting that arrestin-2 is not
involved in agonist-promoted internalization of CXCR4.
Direct ubiquitination of CXCR4 at the plasma membrane is
required for its sorting to the degradative pathway but not for
its internalization (6, 7). Because arrestin-2 also appears to be
required for CXCR4 degradation but not internalization, we
next assessed whether the effect on CXCR4 degradation is due
to a role on CXCR4 ubiquitination. HEK293 cells transfected
with siRNA targeted against arrestin-2 and arrestin-3 or con-
trol siRNA plus HA-tagged CXCR4 and FLAG-tagged ubiq-
uitin were stimulated with or without agonist for 30 min, fol-
lowed by receptor immunoprecipitation and immunoblotting
to detect the incorporation of tagged ubiquitin, as previously
described (7). As shown in Fig. 1F, ubiquitination of CXCR4
was not affected in arrestin-2 or arrestin-3 siRNAdepleted cells
as compared with control siRNA-treated cells, even though
arrestins were substantially depleted (Fig. 1F, bottom panel). In
addition, the ubiquitination status of CXCR4was not altered in
cells that were transfected with a siRNA that targets both arres-
tin-2 and arrestin-3 with respect to mock transfected cells (Fig.
1G), further suggesting that arrestins are not involved in
CXCR4ubiquitination. Taken together, these data indicate that
arrestin-2 is not involved in CXCR4 ubiquitination and inter-
nalization and suggest that its role in CXCR4 degradation is
likely due to a post-internalization function such as endosomal
sorting into the degradative pathway.
We next examined the distribution of CXCR4 in arrestin-2-
depleted HEK293 cells that were treated with or without
CXCL12 using confocal immunofluorescence microscopy. In
the absence of stimulation, CXCR4 was localized predomi-
nantly to the plasma membrane in both control and arrestin-2
siRNA-treated cells, although a portion of CXCR4 was also
localized to intracellular puncta that partially overlapped with
the early endosomal marker EEA1 (Fig. 2A, top panels, control
and arrestin-2) or late endosomal/lysosomal marker LAMP2
(Fig. 2B, top panels, control and arrestin-2), suggesting that
CXCR4 undergoes constitutive internalization and trafficking
to early endosomes and lysosomes. Upon treatment with
CXCL12 for 3 h, in the control treated cells, CXCR4 mostly
co-localized with the late endosomal/lysosomal marker
LAMP2 (Fig. 2B), but not with the early endosomal marker
EEA1 (Fig. 2A), suggesting that CXCR4 traffics efficiently to
lysosomes upon stimulation with CXCL12. In contrast, upon
stimulationwith CXCL12 in the arrestin-2 siRNA-treated cells,
CXCR4 mostly co-localized with EEA1 and not LAMP2, sug-
gesting that transit fromendosomes to lysosomes is impaired as
comparedwith control treated cells. Taken together, these data
suggest that arrestin-2 is required for properCXCR4 trafficking
from early endosomes to lysosomes.
We previously showed that AIP4 is localized to endosomes
and mediates endosomal sorting of CXCR4 (7); therefore, we
next asked whether arrestins facilitate AIP4-mediated traffick-
ing of CXCR4. To address this, we initially determined whether
arrestins interact with AIP4 in cells. HEK293 cells were tran-
siently transfected with HA-tagged arrestin-2 or arrestin-3 and
FLAG-tagged AIP4 or empty vector (pCMV). Whole cell
lysates were subject to immunoprecipitation using a FLAG
antibody followed by immunoblotting to detect arrestin-2 or
arrestin-3 in the immunoprecipitates. As shown in Fig. 3A,
arrestin-2 and arrestin-3 co-immunoprecipitation was ob-
served in cells transfected with FLAG-tagged AIP4 but not in
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FIGURE 1. Arrestin depletion inhibits degradation but not internalization and ubiquitination of CXCR4. A, arrestin siRNA attenuates agonist-mediated
degradation of endogenous CXCR4 in HeLa cells. HeLa cells were transfected with control siRNA (CON) or siRNA against arrestin-2 (Arr2; final concentration, 100
nM), arrestin-3 (Arr3; final concentration, 100 nM), or arrestin-2 and arrestin-3 together (Arr23; final concentration for each, 50 nM). The cells were treated with
vehicle (DMEM containing 0.5% FBS) or CXCL12 (10 nM) for 3 h in DMEM containing 10% FBS supplemented with 50 g/ml cycloheximide. Equal amounts of
cell lysates were subject to SDS-PAGE followed by immunoblotting for endogenous receptor levels. The arrestin levels were assessed using an antibody that
recognizes both arrestin-2 and arrestin-3 from the indicated siRNA transfected cells. The immunoblots were stripped and reprobed for tubulin to assess
loading. Shown are representative immunoblots (IB). The molecular weights are indicated. B, graphical representation of CXCR4 degradation. Immunoblots
were subject to densitometric analysis to quantify receptor levels. The bar graphs represent the average percentages of receptor degraded in cells treated with
CXCL12 as compared with vehicle-treated cells after normalization to tubulin levels. The error bars represent the standard errors of the mean from six
independent experiments. The data were subjected to statistical analysis by a repeated measures analysis of variance followed by a post-hoc Dunnett’s
multiple comparison test (p value 0.01). C, arrestin-2 siRNA attenuates agonist-mediated degradation of HA-CXCR4 in HEK293 cells. HEK293 cells were
transfected with control siRNA (CON) or siRNA against arrestin-2 (Arr2) followed by transfection with HA-tagged CXCR4. After 72 h, the cells were treated with
vehicle (DMEM containing 0.5% FBS) or CXCL12 (10 nM) for 3 h in DMEM containing 10% FBS supplemented with 50 g/ml cycloheximide. Equal amounts of
cell lysates were subjected to SDS-PAGE followed by immunoblotting to detect HA-CXCR4. The arrestin levels were assessed using an antibody that recognizes
both arrestin-2 and arrestin-3 from the indicated siRNA-transfected cells. The immunoblots were stripped and reprobed for tubulin or actin to assess loading.
Shown are representative immunoblots. The molecular weights are indicated. D, graphical representation of HA-CXCR4 degradation. The immunoblots were
subjected to densitometric analysis to quantify receptor levels. The bar graphs represent the average percentages of receptor degraded in cells treated with
CXCL12 as compared with vehicle-treated cells after normalization to tubulin levels. The error bars represent the standard errors of the mean from four
independent experiments. To determine the statistical significance, the data were subjected to an unpaired t test (p value 0.01). E, arrestin-2 does not mediate
agonist-induced internalization of HA-CXCR4. HEK293 cells were transfected with control siRNA (CON) or siRNA against arrestin-2 (Arr-2) followed by transfec-
tion with HA-tagged CXCR4. The cells were treated with 30 nM CXCL12 for 20 min and CXCR4 internalization was assessed by cell surface enzyme-linked
immunosorbent assay. The bar graphs represent the percentages of average cell surface receptor levels internalized in cells treated with CXCL12 as compared
with vehicle treated cells. The error bars represent the standard errors of the mean from four independent experiments. F and G, depletion of arrestin-2 and
arrestin-3 does not affect agonist-induced CXCR4 ubiquitination. HEK293 cells were transfected with control siRNA (CON) or siRNA targeting arrestin-2 (Arr2) or
arrestin-3 (Arr3) (F). The cells were mock (CON) transfected or transfected with siRNA that recognizes both arrestin-2 and arrestin-3 (Arr2/3) (G), followed by
transfection with DNA encoding HA-CXCR4 and FLAG-ubiquitin. The cells were stimulated with 100 nM CXCL12 for 30 min, and CXCR4 ubiquitination was
determined as previously described (6, 7). The arrestin levels were assessed using an antibody that recognizes both arrestin-2 and arrestin-3 from the indicated siRNA
transfected cells. The immunoblots were stripped and reprobed for actin to assess loading. Shown are representative immunoblots. The molecular weights are
indicated. The ubiquitinated CXCR4 levels were assessed by densitometric analysis and the fold increase upon CXCL12 treatment as compared with vehicle treatment
was normalized to receptor levels present in the immunoprecipitates (IP). The bar graph represents receptor ubiquitination observed in arrestin-2/3 siRNA (Arr2/3)-
treated cells as compared with control (CON) treated cells. The error bars represent the S.E. from three independent experiments.
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vector-transfected cells, suggesting that arrestins associatewith
AIP4 in cells.
Todefine the nature of the interaction,we examinedwhether
AIP4 and arrestin-2 interact directly or via an intermediate pro-
tein. Purified arrestin-2 was incubated with glutathione beads
that were coated with full-length AIP4 fused to GST or GST
alone (shown schematically in Fig. 3B), and bound arrestin-2
was detected by immunoblotting. As shown in Fig. 3C, GST-
AIP4, but not GST alone, bound to purified arrestin-2, suggest-
ing a direct interaction betweenAIP4 and arrestin-2. AIP4 gen-
erally binds to its target proteins via its four tandem WW
domains (19, 22); therefore, we next asked whether the interac-
tionwith arrestin-2 ismediated by theWWdomains. As shown
in Fig. 3C, arrestin-2 also bound to a GST fusion protein of the
AIP4 WW domains (GST-WW-I-IV); however, GST-AIP4
appeared to bind better than GST-WW-I-IV, suggesting that
there may be additional sites on AIP4 that bind to arrestin-2.
Alternatively, full-length AIP4 may maintain a more favorable
arrestin-2 binding conformation. Similarly, we observed better
binding of GST-AIP4 thanGST-WW-I-IV toHA-tagged arres-
tin-2 expressed in HEK293 cells (Fig. 3D). Thus, it appears that
theWWdomains, at least in part, mediate the interaction with
arrestin-2. To explore which of the four WW domains of AIP4
mediated the interaction with arrestin-2, we examined the abil-
ity of each individual WW domain to bind to arrestin-2. Equal
amounts of GST fusion proteins containing individual WW
domains were assessed for their ability to interact with HA-
tagged arrestin-2 in whole cell lysates. As shown in Fig. 3E, the
interaction with arrestin-2 is mediated by WW domains I and
II, but not WW domains III and IV of AIP4.
WW domains interact with proline-rich motifs in various
contexts, and because arrestins contain several proline-rich
sequences,wedecidedtouse truncationmutagenesis todetermine
theAIP4-binding regionsonarrestin-2.Various arrestin-2 trunca-
tionmutants used in these studies are shown schematically in Fig.
4A. Initially, we examined two truncation mutants encompassing
the amino-terminal (amino acids 1–260) and carboxyl-terminal
(amino acids 261–418) regions of arrestin-2.Whole cell lysates of
HEK293 cells expressing HA-tagged arrestin-2 truncation
mutants were incubated with glutathione beads coated withWW
domains I–IV fused to GST or GST alone. As shown in Fig. 4B,
GST-WW-I-IV bound to arrestin-2-(1–260) but not arrestin-2-
(261–418). Further truncation of arrestin-2-(1–260) to residues
179 and 161 revealed that binding to AIP4 was most likely medi-
ated by residues located between residues 161 and 260. Interest-
ingly, this region contains a proline-rich stretch within the hinge
region (174–181) that connects the amino- andcarboxyl-terminal
domains of arrestin-2 (23). Mutation of two proline residues to
alanines (arrestin-2-(P180A/P182A)) and deletion of 8 amino
acids (175–182) encompassing the proline residues within this
region in the context of the 1–260 construct failed to abrogate
binding toGST-WW-I-IV (data not shown), suggesting that these
residues are not important for binding to AIP4 and that other
regions may be involved.
To gain further insight into the mechanism by which
arrestins function in AIP4-dependent degradation of CXCR4,
FIGURE 2. CXCR4 accumulates on early endosomes and does not traffic to lysosomes in arrestin-2 depleted cells. HEK293 cells were transfected with
arrestin-2 siRNA followed by transfection of HA-CXCR4-YFP. The cells were stimulated with 10 nM CXCL12 for 3 h and then fixed, permeabilized, and immuno-
stained for either EEA1 (A), an early endosomal marker, or LAMP-2 (B), a late endosomal/lysosomal marker. CXCR4 is shown green (left panels), and EEA1 (A) and
LAMP-2 (B) are shown red (middle panels). Puncta that appear yellow in the merged images (right panels) indicate co-localization of CXCR4 with the endosomal
markers. The insets represent enlarged views of the boxed regions. The bar represents 5 microns. Similar results were observed from three independent
experiments.
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we examinedwhether receptor acti-
vation promotes the interaction
between AIP4 and arrestin-2. Ini-
tially, we compared the ability of
AIP4 to bind to wild-type arrestin-2
and arrestin-2-R169E. The arrestin-
2-R169E mutant is thought to
mimic the formof arrestinwhen it is
bound to activated and phosphoryl-
ated GPCRs and is thus considered
to be “constitutively active” (24).
HEK293 cells were transiently
transfected with either arrestin-2
wild-type or R169Emutant together
with FLAG-tagged AIP4 or empty
vector (pCMV). Whole cell lysates
were subject to immunoprecipita-
tion using the FLAG antibody fol-
lowed by immunoblotting to detect
arrestin-2 in the immunoprecipi-
tates. As shown in Fig. 5A, a single
band corresponding to arrestin-2
was observed in cells transfected
with FLAG-tagged AIP4 but not in
cells transfected with empty vector.
Interestingly, arrestin-2-R169E
showed enhanced binding to FLAG-
taggedAIP4 as comparedwith wild-
type arrestin-2 (Fig. 5A), suggesting
that receptor activation may pro-
mote arrestin-2 binding to AIP4.
To confirm our findings, we next
examined whether activation of
CXCR4 promotes the association
between endogenous AIP4 and
arrestin-2 in HEK293 cells that sta-
bly express HA-tagged CXCR4. The
cells were treated in the absence or
presence of CXCL12 followed by
immunoprecipitation of endoge-
nous AIP4 and immunoblotting to
detect arrestins in the immunopre-
cipitates. As shown in Fig. 5B, incu-
bation of cells with agonist for
15–30 min induced a robust
increase in the amount of arrestin-2
and arrestin-3 detected in AIP4
immunoprecipitates, which dimin-
ished by 60min, indicating that acti-
vation of CXCR4 promotes a time-
dependent interaction between
AIP4 and arrestins.
To determine whether AIP4 and
arrestin-2 co-localize within the
same subcellular compartment,
we employed immunofluorescence
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FIGURE 3. Arrestin-2-binding domains on AIP4. A, AIP4 interacts with nonvisual arrestins. HEK293 cells were
transiently co-transfected with FLAG-tagged full-length AIP4 or empty vector (pCMV) and HA-tagged arres-
tin-2 or arrestin-3. Whole cell lysates (WCL) were subject to immunoprecipitation (IP) using an anti-FLAG M2
monoclonal antibody followed by SDS-PAGE and immunoblotting to detect HA-tagged arrestins in the immu-
noprecipitates. Approximately 1% of WCL used in the immunoprecipitation reaction and one-third of the
immunoprecipitation sample were immunoblotted (IB) to determine the levels of each protein. The molecular
weights are indicated. Shown are representative blots from four independent experiments. B, schematic rep-
resentation of AIP4 GST fusion constructs. AIP4 is characterized by the presence of a C2 domain, four tandem
WW domains, and a catalytic homologous to E6-AP carboxyl-terminal domain. Full-length AIP4 (GST-AIP4) and
a construct encoding the four WW domains (GST-WW-I-IV) were cloned into pGEX-4T2. C, AIP4 interacts directly
with arrestin-2. The indicated GST fusion proteins (1 g) were incubated with purified arrestin-2 (300 ng)
followed by SDS-PAGE and immunoblotting with an anti-arrestin antibody to detect arrestin-2. The input
represents 10 ng of purified arrestin-2. A Coomassie-stained gel is shown to indicate the levels of the GST fusion
proteins used in the binding experiment. The extra bands in the GST-AIP4 lanes represent degradation prod-
ucts co-purified with full-length GST-AIP4. Shown are representative blots from three independent experi-
ments. The molecular weights are indicated. D, the WW domains of AIP4 mediate the interaction with arres-
tin-2. WCL from HEK293 cells expressing HA-arrestin-2 or pcDNA were incubated with GST-AIP4, GST-WW-I-IV,
or GST alone followed by SDS-PAGE and immunoblotting to detect HA-arrestin-2 binding. The input equals 2%
of the lysate that was used in the binding experiment. A Coomassie-stained gel is shown to indicate the levels
of the GST fusion proteins used in the binding experiment. The extra bands in the GST-AIP4 lanes represent
degradation products co-purified with full-length GST-AIP4. Shown are representative blots from three inde-
pendent experiments. The molecular weights are indicated. E, WW domains I and II interact with arrestin-2.
WCL from HEK293 cells expressing HA-arrestin-2 were incubated with GST-AIP4, GST-WW-I-IV, GST fused to
each of the individual four WW domains, or GST alone followed by SDS-PAGE and immunoblotting to detect
HA-arrestin-2 binding. The input equals 0.5% of the lysate that was used in the binding experiment and
approximately one-half of bound sample was immunoblotted. The upper blot was stained with Ponceau S to
show the levels of the GST fusion proteins used in the binding experiment. Shown are representative blots from
three independent experiments. The molecular weights are indicated.
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YFP-arrestin-2, and mCh-AIP4. The cells were treated with
agonist for 30 min, permeabilized, fixed, and observed using a
confocal microscope. As shown in Fig. 5C, in the vehicle-
treated cells, arrestin-2 and AIP4 were mostly diffuse, although
AIP4 was also found in puncta, consistent with its localization
to endosomes (7). In contrast, in the CXCL12-treated cells,
arrestin-2 became punctate and showed strong co-localization
with AIP4. Taken together, these data suggest that arrestin-2
co-localizes with AIP4 on endosomes upon CXCR4 activation,
whichmay facilitate its ability tomediate sorting ofCXCR4 into
the degradative pathway.
DISCUSSION
Here, we establish that arrestin-2 functions in endosomal
sorting of CXCR4 into the degradative pathway (7). Arrestin-2
likely facilitates AIP4-mediated events critical for endosomal
sorting of CXCR4, although the precise mechanism is not
known. Arrestin-2 is likely not a target for ubiquitination by
AIP4 because siRNA-mediated depletion of AIP4 did not have






























































































FIGURE 4. AIP4-binding domains on arrestin-2. A, schematic representa-
tion of arrestin-2 constructs. Truncated versions of arrestin-2 were generated
by PCR and inserted into pcDNA3 in-frame with HA-tag at the amino-terminal
end. B and C, AIP4-binding site is located on the amino-terminal half of arres-
tin-2. WCL from HEK293 cells transiently expressing HA-tagged truncated
versions of arrestin-2, 1–260 and 261– 418 (B) and 1–260, 1–179 and 1–161 (C),
were incubated with glutathione beads coupled to GST-WW-I-IV and GST
alone. The bound samples were resolved by SDS-PAGE, followed by immu-
noblotting (IB) with an anti-HA-antibody (top panel) and Coomassie stain-
ing (bottom panel). The input represents 0.5% of the lysate that was used
in the binding experiment, and one-third of the bound sample was immuno-
blotted. The extra bands in the Coomassie-stained gel represent proteins in
the WCL that bound nonspecifically to GST during the binding experiment.
Shown are representative blots from three independent experiments. The
molecular weights are indicated.
FIGURE 5. AIP4 interacts with arrestin in an activation-dependent man-
ner. A, AIP4 shows enhanced binding to the constitutively active arrestin-2-
R169E mutant. HEK293 cells were transiently transfected with cDNA encod-
ing arrestin-2, arrestin-2-R169E, FLAG-tagged full-length AIP4, pcDNA3, and
pCMV. WCL were subject to immunoprecipitation (IP) using the anti-FLAG M2
monoclonal antibody and immunoblotting using an arrestin polyclonal anti-
body. Shown are representative blots from four independent experiments.
WCL were immunoblotted (IB) to detect expression of each construct. The
molecular weights are indicated. B, the interaction between AIP4 and arres-
tin-2 is mediated by activation of CXCR4. HEK293 cells stably expressing HA-
tagged CXCR4 were serum-starved for 14 –18 h and treated with vehicle or
CXCL12 (30 nM) for 15– 60 min. Equal amounts of WCL were subject to immu-
noprecipitation with an anti-AIP4 monoclonal antibody (G11) or an isotype
control antibody (mouse IgG1) and IB as indicated. Shown are representative
blots from three independent experiments. The molecular weights are indi-
cated. C, arrestin-2 co-localizes with AIP4 on endosomes. HEK293 cells tran-
siently co-transfected with HA-CXCR4, mCh-AIP4, and YFP-arrestin-2 were
serum-starved for 14 –18 h and incubated in the presence of 30 nM CXCL12 or
vehicle for 30 min. The cells were permeabilized, fixed, and analyzed by con-
focal microscopy. AIP4 is shown in red (left panels), whereas arrestin-2 (middle
panels) is shown green. Puncta that co-localize appear yellow in the merged
images (right panels). The insets represent enlarged views of boxed regions.
Scale bar, 5 m. Similar results were observed from three independent
experiments.
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not shown). Arrestin-2 might facilitate CXCR4 stimulated
ubiquitination of HRS, which is AIP4-dependent (7). Interest-
ingly, HRS also mediates lysosomal targeting of the epidermal
growth factor receptor. However, AIP4, despite its co-localiza-
tion with HRS on endosomes, functions in sorting CXCR4 and
not epidermal growth factor receptor, suggesting that the endo-
somal sorting activity of AIP4 is specific for a subset of recep-
tors targeted to lysosomes (7, 21). It is possible that the speci-
ficity of AIP4 for CXCR4 endosomal sorting is a function of its
ability to bind to arrestin-2 on endosomes. Regardless, our data
support a model whereby arrestin-2 interacts with AIP4 on
endosomes, where it likely modulates endosomal functions of
AIP4 that are critical for lysosomal targeting of CXCR4 (7, 21).
Although the interaction between AIP4 and arrestin-2 in
cells is regulated by activation of CXCR4, we can detect basal
binding between the proteins when overexpressed in the
absence of activated receptor (Fig. 3). Itmay be possible that the
AIP4-binding site is only partially accessible in the inactive con-
formation and that arrestin-2 activationmakes it more accessi-
ble leading to greater AIP4 binding. Alternatively, it is possible
that there are multiple AIP4-binding sites in arrestin-2. For
example, a low affinity binding site may be accessible when
arrestin-2 is in the inactive conformation, and a second, high
affinity site may become accessible upon arrestin-2 activation,
leading to a stronger interaction with AIP4. Nevertheless, our
data indicate that AIP4 and arrestin-2 interact directly in vitro,
and their association in cells is regulated by CXCR4 activation.
In addition, we have identified the amino-terminal region of
arrestin-2 and AIP4 WW domains I and II as the binding
regions that may facilitate the interaction in cells.
Typically, arrestin binding to activated and phosphorylated
GPCRs occurs at the plasma membrane, which is thought to
promote a conformational change in arrestin exposing the bur-
ied carboxyl-terminal end that binds to partners such as clath-
rin and -adaptin (13). Because CXCR4 activation promotes
AIP4 binding to arrestin-2, arrestin-2may be recruited to phos-
phorylated CXCR4 before it interacts with AIP4. However,
because the AIP4-binding site maps to the amino-terminal half
of arrestin-2, we believe the mechanism of the interaction will
be distinct from that for clathrin and -adaptin, although a
conformational change in arrestin-2 is likely required.
Interestingly, the arrestin-2-AIP4 interaction is maximal
after 15–30 min of agonist treatment, when both proteins co-
localize on endocytic vesicles. Thus, it is possible that arrestin-2
binds to phosphorylated CXCR4 and AIP4 at the plasmamem-
brane, and all three proteins co-traffic as a complex to endo-
somes. Arrestins have been shown to form stable complexes
with certainGPCRs and several signalingmolecules that persist
for some time on endosomes (25), but whether this is true for
CXCR4, AIP4, and arrestin-2 remains to be determined. It is
also possible that arrestin-2 interacts with phosphorylated
CXCR4 at the plasma membrane, which co-internalize as a
complex and once on endosomes somehow interacts with the
endosomal pool ofAIP4.Thismay also explainwhy arrestin-2 is
not important for ubiquitination of the receptor at the plasma
membrane. We show that in addition to not being involved in
the ubiquitination of CXCR4, arrestin-2 is not involved in its
internalization. It is possible that arrestin-2 mediates desensi-
tization of CXCR4, although this function has been previously
assigned to arrestin-3 (16), which possibly also mediates
CXCR4 internalization (15, 17). Alternatively, arrestin-2 may
instead be directly recruited to endosomes by activated
CXCR4, where it carries out its endosomal sorting function.
Regardless of the mechanism, our data reveal that arrestin-2
co-localizes with AIP4 on endocytic vesicles, where it likely
functions to mediate lysosomal targeting of CXCR4.
In conclusion, we describe a novel function for arrestin-2 as
an endosomal sorting molecule together with AIP4 to mediate
CXCR4 entry into a degradative pathway. This function devi-
ates from the general paradigm that arrestins serve as adaptors
for clathrin-dependent internalization of GPCRs at the plasma
membrane and suggests that arrestins may also serve as endo-
somal adaptor proteins required for sorting GPCRs into the
degradative pathway.
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